An overview of the antiretroviral market

被引：6

作者：

Camponeschi, Geannan ^{[1
]}

Fast, Jessica ^{[1
]}

Gauval, Marianne ^{[1
]}

Guerra, Katherine ^{[1
]}

Moore, Meredith ^{[1
]}

Ravinutala, Siddharth ^{[1
]}

Ripin, David ^{[1
]}

Shepel, Vadim ^{[1
]}

机构：

[1] Clinton Hlth Access Initiat, Boston, MA 02127 USA

来源：

CURRENT OPINION IN HIV AND AIDS | 2013年 / 8卷 / 06期

关键词：

antiretroviral; market regimen; WHO treatment guidelines;

D O I：

10.1097/COH.0000000000000012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Purpose of reviewAn understanding of the current state of the antiretroviral marketplace is an important context in which to consider drug optimization work.Recent findingsThe antiretroviral marketplace has undergone a remarkable evolution over the past 11 years, expanding from serving less than 300000 patients in low and middle-income countries in 2002 to almost 10 million patients today. In addition to dramatic growth, a steady and rapid improvement in the drugs and drug regimens used to treat patients has characterized a rapidly changing market.SummaryThe antiretroviral marketplace has been characterized by rapid growth and a succession of improving drugs and regimens over the past 11 years. The dynamic and innovative marketplace provides a strong platform from which to introduce new, optimized drugs and regimens to better serve patients' health needs.

引用

页码：535 / 543

页数：9

共 12 条

[1]

[Anonymous], 7 IAS C HIV PATH TRE

[2]

[Anonymous], 2012, M INV CHALL TIPP DEP

[3]

[Anonymous], 2013, GLOB UPD HIV TREATM

[4] HIV viral load monitoring in resource-limited regions: Optional or necessary? [J].

Calmy, Alexandra ;

Ford, Nathan ;

Hirschel, Bernard ;

Reynolds, Steven J. ;

Lynen, Lut ;

Goemaere, Eric ;

de la Vega, Felipe Garcia ;

Perrin, Luc ;

Rodriguez, William .

CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :128-134

[5]

Global Health Observatory, 7 IAS C HIV PATH TRE

[6]

Kates Jennifer., 2012, Financing the Response to AIDS in Lowand Middle-Income Countries: International Assistance from the G8, European Commission and Other Donor Governments in 2009

[7] Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis [J].

Mills, Anthony M. ;

Nelson, Mark ;

Jayaweera, Dushyantha ;

Ruxrungtham, Kiat ;

Cassetti, Isabel ;

Girard, Pierre-Marie ;

Workman, Cassy ;

Dierynck, Inge ;

Sekar, Vanitha ;

Abeele, Carline Vanden ;

Lavreys, Ludo .

AIDS, 2009, 23 (13) :1679-1688

[8]

Orrell C, 2007, ANTIVIR THER, V12, P83

[9]

Pan American Health Organization, 2012, ANT THER SPOTL PUBL

[10]

Technicalupdate on treatment optimization, 2012, TECHN UPD TREATM OPT

← 1 2 →